May 28 (Reuters) - Johnson & Johnson:
* JOHNSON & JOHNSON TO OBTAIN RIGHTS TO A CLINICAL-STAGE
BISPECIFIC ANTIBODY TO ADDRESS DISTINCT PATIENT NEEDS IN ATOPIC
DERMATITIS
* J&J - PROPOSED DEAL FOR ALL-CASH TRANSACTION OF
APPROXIMATELY
$1.25 BILLION
* J&J - PROPOSED DEAL FOR ALL-CASH TRANSACTION OF
APPROXIMATELY
$1.25 BILLION
* J&J: ENTERS AGREEMENT WITH NUMAB THERAPEUTICS TO ACQUIRE
ITS
WHOLLY OWNED SUBSIDIARY FOR GLOBAL RIGHTS TO NM26
Source text for Eikon:
Further company coverage: